Biohit Oyj of Helsinki at MEDICA 2018 in Düsseldorf -- COMPAMED Trade Fair

Biohit Oyj

Laippatie 1, 00880 Helsinki
Finland
Telephone +358 9 773861
Fax +358 9 7732867
info@biohit.fi

Hall map

MEDICA 2018 hall map (Hall 3A): stand 3AD14

Fairground map

MEDICA 2018 fairground map: Hall 3A

Our range of products

Product categories

  • 03  Diagnostics
  • 03.02  Immunochemistry testing, immunology testing
  • 03.02.02  Diagnostic rapid tests

Diagnostic rapid tests

Our products

Product category: Diagnostic rapid tests

Diagnostic tests

The diagnostic product range of Biohit includes the GastroPanel® examinations, which are used to aid diagnosis of Helicobacter pylori infection and atrophic gastritis from a blood sample. They are also ideal tools for identification of patients at increased risk of gastric cancer, peptic ulcer disease, gastroesophageal reflux disease (GERD) and deficiencies of vitamin B12, calcium and iron. In addition to this, Biohit offers Quick tests for the detection of

Lactose intolerance
Helicobacter pylori infection
Celiac disease
Screening of colorectal cancer
Acetaldehyde binding products
An acid-free stomach is the primary risk factor in gastric cancer. According to recent research, it is also a significant risk factor in oesophageal cancer. Acetium® is a CE marked product developed and patented by Biohit Oyj. It is intended for persons with a low-acid or anacidic stomach

Monoclonal antibodies
Biohit also develops and manufactures monoclonal antibodies for research use and use as raw materials for diagnostic industry.

Instruments
Adopting a systems approach, Biohit also provides laboratory equipment, such as microplate instruments and automates, as well as liquid handling products to support Biohit ELISA tests.

More Less

About us

Company details

Biohit HealthCare – Innovating for Health
Biohit Oyj 
Biohit Oyj is a globally operating Finnish biotechnology company. We produce innovative products and services to promote research and early diagnosis. 

Innovations and patents
Biohit's operations are based on a goal-oriented and long-term innovation and patenting strategy. Biohit works with scientific communities to produce new technologies, products and services based on research results and innovations that can be used to develop safe and cost-effective diagnostic tests for the early detection and prevention of diseases of the gastrointestinal tract.

Diagnostics
The key objective of the diagnostics business is to prevent diseases of the gastrointestinal tract. Biohit HealthCare has products and analysis systems for the early diagnosis of gastrointestinal diseases, such as the blood-sample based GastroPanel® examinations for the diagnosis of stomach illnesses and associated risks, quick tests for the diagnosis of lactose intolerance and Helicobacter pylori infection in connection with gastroscopy, and the ColonView examination for the early detection of fecal occult intestinal bleeding (faecal occult blood) that indicates a risk of colorectal cancer. The Acetium innovation was developed to reduce carcinogenic acetaldehyde in the gastrointestinal tract. 

Biohit Group worldwide
Biohit is headquartered in Helsinki, Finland, and has subsidiaries in Italy and the UK. The Biohit Group employs around 50 people. Biohit's series B share (BIOBV) is quoted on NASDAQ OMX Helsinki, Small cap/Healthcare since 1999. Biohit's products are sold by many distributors around the world. More information about the share and financials is available in the Investors section of this site.

More Less